Emily Darlington

It is a pleasure to serve under your chairmanship, Mr Mundell. I want to start with the expression, “Do no harm.” To be clear for the people who have come to speak to me—parents and young people themselves—we are doing them harm by not giving them the treatment they need, with the wait times of six years, and potentially in respect of puberty blockers, where that is agreed with their healthcare professionals. My overarching concern is that the clinical trial was suggested in the Cass review. It was proposed and designed in conjunction with the MHRA, but then the MHRA changed its mind. Why was that? Dr Hilary Cass said: “There are no new research findings and the MHRA hasn’t presented any new evidence. It feels to me like they are responding to political pressure rather than to science.” That is what she said; I was quoting her verbatim. It was her review that the people around this Chamber wanted us to listen to and to make changes in response to, so we have to listen to her in this instance as well. The MHRA should operate without any political interference or fear of legal action, yet the MHRA itself referenced potential legal action in relation to the trial as one of the reasons why it changed its mind. That is a problem. The MHRA is there to make sure that anything from clinical trials to medical technologies and new drugs are dealt with on the basis of science and science alone.